why Ginkgo Bioworks Holdings Inc. [DNA] is a Good Choice for Investors After New Price Target of $9.14

Related

Ginkgo Bioworks Holdings Inc. [NYSE: DNA] loss -7.51% or -0.22 points to close at $2.71 with a heavy trading volume of 22208571 shares. The company report on April 22, 2022 that Ginkgo Bioworks to Expand Platform Capabilities in Agricultural Biologicals and Launch Flagship Partnership with Bayer.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Planned transaction expands Ginkgo’s horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to customers of all sizes in the agriculture industry .

Under the proposed transaction, Ginkgo to acquire Bayer’s West Sacramento agricultural biologicals site and team, adding a 175,000-square-foot R&D facility with pilot scale fermentation, formulation, and greenhouse facilities, along with access to Bayer’s large agricultural strain collection.

It opened the trading session at $2.95, the shares rose to $2.95 and dropped to $2.65, the range by which the price of stock traded the whole day. The daily chart for DNA points out that the company has recorded -81.19% loss over the past six months. However, it is still -3.44% lower than its most recent low trading price.

If we look at the average trading volume of 18.27M shares, DNA reached to a volume of 22208571 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Ginkgo Bioworks Holdings Inc. [DNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $9.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cowen have made an estimate for Ginkgo Bioworks Holdings Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 02, 2022. While these analysts kept the previous recommendation, Goldman raised their target price to Neutral. The new note on the price target was released on February 23, 2022, representing the official price target for Ginkgo Bioworks Holdings Inc. stock. Previously, the target price had yet another raise to $6, while BofA Securities analysts kept a Neutral rating on DNA stock.

The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc. is set at 0.36, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 13.89. The Price to Book ratio for the last quarter was 2.77, with the Price to Cash per share for the same quarter was set at 0.96.

Trading performance analysis for DNA stock

Ginkgo Bioworks Holdings Inc. [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.55. With this latest performance, DNA shares dropped by -23.23% in over the last four-week period, additionally sinking by -81.19% over the last 6 months – not to mention a drop of -73.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 36.81, with the RSI for the last a single of trading hit 32.88, and the three-weeks RSI is set at 38.58 for Ginkgo Bioworks Holdings Inc. [DNA]. The present Moving Average for the last 50 days of trading for this stock 3.54, while it was recorded at 3.06 for the last single week of trading, and 8.30 for the last 200 days.

Ginkgo Bioworks Holdings Inc. [DNA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Ginkgo Bioworks Holdings Inc. [DNA] shares currently have an operating margin of -582.43 and a Gross Margin at +53.93. Ginkgo Bioworks Holdings Inc.’s Net Margin is presently recorded at -583.12.

Return on Equity for this stock declined to -243.13, with Return on Assets sitting at -176.62.

Ginkgo Bioworks Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.80 and a Current Ratio set at 12.80.

An analysis of insider ownership at Ginkgo Bioworks Holdings Inc. [DNA]

There are presently around $2,560 million, or 75.80% of DNA stock, in the hands of institutional investors. The top three institutional holders of DNA stocks are: VIKING GLOBAL INVESTORS LP with ownership of 311,971,018, which is approximately 2.98% of the company’s market cap and around 0.40% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 167,752,680 shares of the stock with an approximate value of $454.61 million in DNA stocks shares; and GENERAL ATLANTIC, L.P., currently with $302.35 million in DNA stock with ownership of nearly -2.89% of the company’s market capitalization.

Positions in Ginkgo Bioworks Holdings Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 117 institutional holders increased their position in Ginkgo Bioworks Holdings Inc. [NYSE:DNA] by around 181,238,171 shares. Additionally, 66 investors decreased positions by around 45,935,556 shares, while 28 investors held positions by with 717,590,431 shares. The mentioned changes placed institutional holdings at 944,764,158 shares, according to the latest SEC report filing. DNA stock had 74 new institutional investments in for a total of 70,203,225 shares, while 39 institutional investors sold positions of 25,907,968 shares during the same period.